埃克替尼治疗复治晚期非小细胞肺癌

Icotinib Retreatment Advanced Non-small Cell Lung Cancer

目的研究分析埃克替尼治疗复治晚期非小细胞肺癌的效果。方法取材于近三年来我院就诊的复治晚期非小细胞肺癌患者,数量为48例,对患者使用埃克替尼进行治疗,每次服用125 mg,每日三次,统计治疗过程中患者出现不良反应的情况并分析埃克替尼的作用效果。结果通过服用埃克替尼治疗复治晚期非小细胞肺癌患者,患者治疗效果显著,其中1例患者病情完全缓解,所占比例为2.08%,17例患者病情得到一定的控制,所占比例为35.42%,15例患者病情没有发生改善,同时也未出现加重情况,所占比例为31.25%,15例患者病情出现加重情况,所占比例为31.25%,患者在治疗中会对药物产生不良反应,其中多为皮疹和腹泻,及时的制定治疗方案,有效解决了患者的不良反应问题。结论使用埃克替尼治疗复治晚期非小细胞肺癌,大部分患者的病情得到了有效的改善,具有较高的治疗效果,而且治疗过程中患者对药物产生的不良反应危害较小,在患者的忍受范围内,具有较高的安全性,应用价值显著。

Objective To study the icotinib retreatment advanced non-small cell lung cancer. Methods Based on the recent three years in our hospital for treatment of recurrent advanced non-small cell lung cancer patients, the number of 48 cases of patients with icotinib treatment, each taking 125 mg, three times daily, adverse reactions and analysis for effect, and he had statistical treatment process. Results By taking icotinib for treatment of treatment of patients with advanced non-small cell lung cancer patients, the treatment effect is remarkable, among which 1 cases were complete remission, accounted for 2.08 %, 17 cases of patients got some control, the proportion of 35.42 %, 15 cases of patients had no improvement, but also did not appear to increase the situation, the proportion of 31.25 %, 15 cases were aggravated, the proportion of 31.25 %, patients will have adverse reactions to drugs in the treatment, the rash and diarrhea, timely treatment, effectively solve the problem of adverse reactions of patients. Conclusion The use of icotinib retreatment advanced non-small cell lung cancer, most patients were improved, has high curative effect, and adverse reaction in the treatment of drug in patients with less harm, in patients with tolerance range, high security, obvious application value.